Catalyst

Slingshot members are tracking this event:

Bridgebio's (BBIO) Infigratinib (BBP-831) in Cholangiocarcinoma PDUFA date Estimated for June 1, 2021, based on 6-month timeline

Source Link:
https://bridgebio.com/news/bridgebio-pharma-and-affiliate-qed-therapeutics-announce-fda-acceptance-of-new-drug-application-for-infigratinib-for-the-treatment-of-cholangiocarcinoma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BBIO Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
May 28, 2021
Occurred Source:
https://bridgebio.com/news/bridgebio-pharmas-affiliate-qed-therapeutics-and-partner-helsinn-group-announce-fda-approval-of-truseltiq-infigratinib-for-patients-with-cholangiocarcinoma
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Bbp-831, Infigratinib, Cholangiocarcinoma
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.